Health has approved the financing of two new biological drugs erenumab y galcanezuma for this disorder. They act against the CGRP gene, directly related to the appearance of migraine episodes.
They are treatments thatand will be prescribed in a restricted way, that is, in patients who suffer at least 8 migraine crisis per month and who have not responded to other therapies.
The treatment integrates a novelty in its administration since it will do every 4 weeks and can be self-administered by the patient after receiving the appropriate training.
During the presentation of the drugs last Wednesday in Madrid, the head of the Headache Unit of the Clinical Hospital of Madrid Jesus Porta-Etessam, said that "This monthly administration, compared to the daily pill, is very important for the patient, since the feeling of illness is eliminated."
The results of clinical trials of both erenumab as the galcanezumab demonstrate that it is effective in reducing more than 50% of migraine days per month. In a significant percentage of patients the effectiveness reaches 70%, and there are even patients who have reached 100%.
Looking ahead, this information will allow migraine classification based on the response to drugs. In this regard, the European Medicines Agency (EMA) has authorized drugs as Preventive treatment in adults who suffer four or more days of migraine per month.